Welcome to our dedicated page for Viking Therapeutics SEC filings (Ticker: VKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viking Therapeutics, Inc. (NASDAQ: VKTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances a clinical-stage pipeline in metabolic and endocrine disorders. Viking’s Form 8-K filings, for example, report material events such as quarterly financial results and top-line clinical data from trials of VK2735, the company’s dual GLP-1/GIP receptor agonist being developed for obesity and other metabolic conditions. One 8-K references a press release announcing financial results and a corporate update, while another notes top-line Phase 2 results from the oral tablet formulation of VK2735.
Through SEC reports such as 8-K, investors can track how Viking communicates progress in its Phase 3 VANQUISH program for subcutaneous VK2735, Phase 2 and earlier-stage work on oral VK2735, and development of VK2809 for lipid and liver disorders and VK0214 for X-linked adrenoleukodystrophy. These filings complement press releases that describe statistically significant weight loss outcomes, safety and tolerability profiles, and achievement of primary and secondary endpoints in key studies.
On Stock Titan, Viking’s SEC filings are paired with AI-powered tools that summarize and explain the contents of lengthy documents. Investors can quickly understand the implications of quarterly updates, clinical data disclosures, and other material events without reading every line of each filing. Real-time updates from EDGAR ensure that new 8-Ks and other forms appear promptly, while AI-generated highlights help users focus on items such as clinical trial milestones, pipeline strategy, and financial condition as reported by Viking Therapeutics in its official SEC submissions.